// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

Ken Kato - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Fluorouracil

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.

John V. Reynolds - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Capecitabine

Exploring real-world outcomes with nivolumab plus chemotherapy in patients with advanced gastroesophageal adenocarcinoma.

Clara Chen - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

Impact of obesity on postoperative outcomes in patients undergoing esophagectomy for resectable esophageal cancer.

Nikhil Patel - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.

Eric Raymond - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Tislelizumab

Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.

Mariela A. Blum Murphy - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Surpass Cream

Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.

Mark R. Middleton - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Capecitabine and oxaliplatin

MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).

Hazel Lote - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Trastuzumab

Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).

Avani Athauda - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).

Anderley Gordon - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Avelumab

Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).

Ansh Kapil - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Trastuzumab

Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).

Keun-Wook Lee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Tislelizumab

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Tislelizumab

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).

Linda Wu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Atezolizumab

Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.

Josep M Llovet - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Pembrolizumab

Incidence and costs associated with clinically significant events in real-world patients with unresectable hepatocellular carcinoma on systemic therapy.

Marcus Healey - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Atezolizumab

Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

Richard S. Finn - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Regorafenib

Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.

Mohamed Bouattour - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Gemcitabine

A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.

Jamie Partridge - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Atezolizumab

Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.

Claudia A.M. Fulgenzi - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Pembrolizumab

Copyright © 2026. QuantiNova All rights reserved